Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TYMS | P04818 | 2/20 | 0.39 |
| ▸ | TK1 | P04183 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5908156 | 0.90 | TYMS (0.42) | LMNASMN1; SMN2TYMS | |
| SCHEMBL5908160 | 0.86 | POLG (0.39) | — | |
| SCHEMBL5908162 | 0.84 | LMNA (0.42) | LMNASMN1; SMN2TYMS | |
| SCHEMBL5694113 | 0.80 | POLB (0.42) | LMNAP2RY6 | |
| SCHEMBL5694389 | 0.80 | DNMT1 (0.40) | LMNANT5E | |
| SCHEMBL5694199 | 0.78 | CA5A (0.42) | LMNASMN1; SMN2NT5E | |
| SCHEMBL5694044 | 0.77 | POLG (0.38) | — | |
| SCHEMBL5694102 | 0.77 | LMNA (0.36) | LMNASMN1; SMN2 | |
| SCHEMBL5694100 | 0.76 | NT5E (0.48) | LMNASMN1; SMN2NT5E | |
| SCHEMBL5694116 | 0.76 | LMNA (0.44) | LMNASMN1; SMN2TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1645561-A1 | METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2006-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | LMNA 321/4885SMN1; SMN2 1507/4885TYMS 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.